CCM
AKYA

CAAS Capital Management’s Akoya BioSciences AKYA Stock Holding History

CAAS Capital Management’s Portfolio AKYA Stock Details AKYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-50,500
Closed -$977K – 930
2021
Q2 		$977K Buy
+50,500
New +$1.04M 0.02% 568

Other funds holding AKYA

BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

CAAS Capital Management's AKYA Position: Q3 2021 in Review

CAAS Capital Management sold out of Akoya BioSciences (AKYA) in Q3 2021, closing a stake of 50,500 shares — an estimated $977K sold.

CAAS Capital Management first reported a position in AKYA in Q2 2021 and held it in 1 quarter. The position peaked at $977K in Q2 2021. 47 funds tracked by Wall St. Rank hold AKYA as of Q3 2021.

  • CAAS Capital Management reported no remaining Akoya BioSciences position as of Q3 2021 after selling out during the quarter.
  • CAAS Capital Management sold 50,500 Akoya BioSciences shares in Q3 2021, an estimated $977K.
  • CAAS Capital Management first reported a position in Akoya BioSciences in Q2 2021 and held it in 1 quarter.
  • CAAS Capital Management's Akoya BioSciences position peaked at $977K in Q2 2021.
  • 47 funds tracked by Wall St. Rank held Akoya BioSciences as of Q3 2021.

Based on CAAS Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.